All In Biotech

Drug Trial Radar · NCT07636928

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

A Phase 1, Open-Label, Single Dose Study to Assess the Absolute Bioavailability, Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]VH4524184 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Aug 20, 2026

Study completion Aug 20, 2026

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.

Conditions

  • HIV Infections

Interventions

  • VH4524184Drug

    One dose of VH4524184 is administered to participants at time zero on Day 1 (Period 1).

  • [14C]VH4524184 microdoseDrug

    A radiolabelled microdose of \[14C\]VH4524184 is administered 2.5 hours after VH4524184 dose administration on Day 1 (Period1).

  • [14C]VH4524184Drug

    One dose of radiolabelled \[14C\]VH4524184 is administered to participants at Day 15 (Period 2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute bioavailability (F oral) of VH4524184 (Period 1)Time frame: Day 1 up to Day 14
  2. Amount of total radioactivity (TRA) excreted in urine (Ae urine) (Period 1)Time frame: Day 1 up to Day 14
  3. Amount of TRA excreted in urine (Ae urine) (Period 2)Time frame: Day 15 up to Day 43
  4. Amount of TRA excreted in feces (Ae feces) (Period 1)Time frame: Day 1 up to Day 14
  5. Amount of TRA excreted in feces (Ae feces) (Period 2)Time frame: Day 15 up to Day 43
  6. Amount of TRA excreted in vomitus (Ae vomit) (Period 1)Time frame: At Day 1
  7. Amount of TRA excreted in vomitus (Ae vomit) (Period 2)Time frame: At Day 15
  8. Total amount of TRA excreted (Ae total) (Period 1)Time frame: From Day 1 up to Day 14
  9. Total amount of TRA excreted (Ae total) (Period 2)Time frame: Day 15 up to Day 43
  10. Fraction of TRA excreted in urine (fe urine) (Period 1)Time frame: Day 1 up to Day 14
  11. Fraction of TRA excreted in urine (fe urine) (Period 2)Time frame: Day 15 up to Day 43
  12. Fraction of TRA excreted in feces (fe feces) (Period 1)Time frame: Day 1 up to Day 14
  13. Fraction of TRA excreted in feces (fe feces) (Period 2)Time frame: Day 15 up to Day 43
  14. Fraction of TRA excreted in vomitus (fe vomit) (Period 1)Time frame: At Day 1
  15. Fraction of TRA excreted in vomitus (fe vomit) (Period 2)Time frame: At Day 15
  16. Total fraction of TRA excreted (fe total) (Period 1)Time frame: Day 1 up to Day 14
  17. Total fraction of TRA excreted (fe total) (Period 2)Time frame: Day 15 up to Day 43
  18. Maximum concentration (Cmax) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  19. Maximum concentration (Cmax) of VH4524184 in plasma (Period 2)Time frame: Day 15 to Day 43
  20. Maximum concentration (Cmax) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  21. Maximum concentration (Cmax) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
  22. Maximum concentration (Cmax) of TRA in plasma (Period 2)Time frame: Day 15 to Day 43
  23. Cmax of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
  24. Cmax of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
  25. Time to maximum concentration (tmax) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  26. Time to maximum concentration (tmax) of VH4524184 in plasma (Period 2)Time frame: Day 15 to Day 43
  27. Time to maximum concentration (tmax) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  28. Time to maximum concentration (tmax) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
  29. Time to maximum concentration (tmax) of TRA in plasma (Period 2)Time frame: Day 15 to Day 43
  30. Time to maximum concentration (tmax) of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
  31. Time to maximum concentration (tmax) of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
  32. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  33. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of VH4524184 in plasma (Period 2)Time frame: Day 15 to Day 43
  34. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  35. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
  36. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in plasma (Period 2)Time frame: Day 15 to Day 43
  37. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
  38. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
  39. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  40. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of VH4524184 in plasma (Period 2)Time frame: Day 15 up to Day 43
  41. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of [14C]VH4524184 in plasma (Period 1)Time frame: Day 1 to Day 14
  42. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in plasma (Period 1)Time frame: Day 1 to Day 14
  43. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in plasma (Period 2)Time frame: Day 15 to 43
  44. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in whole blood (Period 1)Time frame: Day 1 to Day 14
  45. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in whole blood (Period 2)Time frame: Day 15 to Day 43
  46. Amount of VH4524184 excreted in urine (Ae urine) (Period 2)Time frame: Day 15 to Day 43
  47. Fraction of VH4524184 excreted in urine (fe urine) (Period 2)Time frame: Day 15 to Day 43
  48. Renal clearance of VH4524184 (CL R) (Period 2)Time frame: Day 15 to Day 43

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Groningen, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.